Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo plus usual pharmacological care Disease activity ‐ not measured · systemic lupus erythematosus Exercise as adjunctive therapy for systemic lupus erythematosus (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo plus usual pharmacological care Quality of life ‐ not measured · systemic lupus erythematosus Exercise as adjunctive therapy for systemic lupus erythematosus (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo plus usual pharmacological care Serious adverse events ‐ not reported · systemic lupus erythematosus Exercise as adjunctive therapy for systemic lupus erythematosus (2023) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy manual and telephone support vs usual care Disease activity · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy manual and telephone support vs usual care Flare‐ups/relapse · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Cognitive behavioural therapy manual and telephone support vs usual care Quality of life · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based disease monitoring vs sham monitoring Disease activity · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Web‐based disease monitoring vs sham monitoring Flare‐ups/relapse · people with inflammatory bowel disease Remote care through telehealth for people with inflammatory bowel disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 6. Patients, caregivers, and providers described a number of privacy and confidentiality issues when services were provided at home. These included the increased privacy of being able to exercise at home but also the loss of privacy when e... Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 7. Patients regarded in‐person home‐based rehabilitation and telerehabilitation services as convenient and less disruptive of everyday activities. Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 9. Healthcare providers highlighted the importance of personalising the service to each patient’s needs and resources at home. Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 10. Patients, caregivers, healthcare providers and other stakeholders described how telerehabilitation changed the nature of the patient‐provider relationship. This included overcoming physical barriers to communication and enabling quick ... Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 11. Healthcare providers and patients described some aspects of telerehabilitation services at home as challenging. Healthcare providers described problems in assessing patients, their environment, and whether they were performing exercise... Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Finding 12. Patients, caregivers, healthcare providers and other stakeholders regarded telerehabilitation as an opportunity to make rehabilitation services more accessible. Factors that influence the provision of home‐based rehabilitation services for people needing… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychological interventions vs inactive control (usual care care, attention control, waitlist) Parental self‐harm ‐ post‐intervention ‐ not reported · parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Trauma‐related symptoms ‐ post‐intervention ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Substance use ‐ post‐intervention ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Parent relationship quality ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Parental self‐harm ‐ post‐intervention ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Parent–child relationship ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Service system approaches vs inactive control (usual care care, attention control, waitlist) Parenting skills ‐ post‐intervention ‐ not reported · for parents who are experiencing CPTSD symptoms or have experienced maltreatment in their childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Parenting interventions vs inactive control (usual care care, attention control, waitlist) Substance use ‐ post‐intervention ‐ not reported · parents who are experiencing CPTSD symptoms or have experienced maltreatment in childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Parenting interventions vs inactive control (usual care care, attention control, waitlist) Parent relationship quality ‐ post‐intervention ‐ not reported · parents who are experiencing CPTSD symptoms or have experienced maltreatment in childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Parenting interventions vs inactive control (usual care care, attention control, waitlist) Parental self‐harm ‐ post‐intervention ‐ not reported · parents who are experiencing CPTSD symptoms or have experienced maltreatment in childhood Interventions from pregnancy to two years after birth for parents experiencing complex post‐traumatic stress… (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Pain · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol All‐cause mortality during initial hospitalization · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Morphine vs paracetamol Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Major neurodevelopmental disability in children aged three to five years · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Cognitive and educational outcomes in children more than five years old · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Severe retinopathy of prematurity (defined as stage 3 or greater) · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Tramadol vs no treatment or placebo Severe intraventricular hemorrhage (grade 3 or greater) on cranial ultrasound, as per Papile classification · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Pain · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Fentanyl vs tramadol Major neurodevelopmental disability in children aged 18 to 24 months · postoperative pain in preterm and term infants Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs different infusion regimens of IVIG Acute coronary syndrome (such as MI or coronary thrombus) (up to 7 weeks) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Need for additional treatment · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs prednisolone Length of hospital stay (days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Primary treatment with intravenous immunoglobulin (IVIG) vs acetylsalicylic acid (ASA) Length of hospital stay (days) · people undergoing initial treatment for KD Intravenous immunoglobulin for the treatment of Kawasaki disease (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Any type of hormonal contraception (estrogen plus progestin or progestin‐only) vs no contraception Venous thromboembolism ‐ not measured · COVID‐19 positive patients Risk of thromboembolism in patients with COVID‐19 who are using hormonal contraception (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Any type of hormonal contraception (estrogen plus progestin or progestin‐only) vs no contraception Arterial thromboembolism ‐ not measured · COVID‐19 positive patients Risk of thromboembolism in patients with COVID‐19 who are using hormonal contraception (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Any type of hormonal contraception (estrogen plus progestin or progestin‐only) vs no contraception Acute respiratory distress syndrome ‐ not measured · COVID‐19 positive patients Risk of thromboembolism in patients with COVID‐19 who are using hormonal contraception (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Combined hormonal contraception (estrogen plus progestin) vs no contraception Arterial thromboembolism ‐ not measured · COVID‐19 positive patients Risk of thromboembolism in patients with COVID‐19 who are using hormonal contraception (2023) · Cochrane | no estimate extracted | NR | No studies |